ALXN News and Press, Alexion Pharmaceuticals Inc. From 10/12/20

– New 100 mg/mL formulation will reduce infusion time by approximately 60 percent, lessening the burden on patients – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ...

Big banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to the uncertainty of forecasting numbers amid a pandemic. Of note, the 12 largest U.S. banks are all forecast to report a profit. Overall, Q3 profit for S&P 500 companies ...

- Four abstracts accepted for presentation, including new clinical trial analyses that provide further support for the safety and efficacy of ULTOMIRIS ® (ravulizumab-cwvz) for the treatment of pediatric patients with atypical hemolytic uremic syndrome (aHUS) - Al...

Alexion Pharmaceuticals ([[ALXN]] +1.5%) breaks higher after being in negative territory for most of the morning.Betaville is suggesting that the company has drawn interest from potential private equity buyers.Last month, it as speculation about Biogen interest that sent shares higher.ALXN ha...

Biotechs are one of the most interesting and exciting parts of the market. The sector is breaking out to new highs following a long consolidation period from 2014 to 2020. Four of the most promising stocks are SGEN, ALXN, IMMU, and FATE. Investors should have some allocation to biotech st...

Alexion’s just-released revision to 2020 revenue guidance suggests continuing top line momentum. Given the strong performance through the pandemic, we believe there is even more room for growth as margins hold up. However, shares have underperformed the broader market, and ...

Alexion Pharmaceuticals (ALXN) increases its FY20 revenue guidance by more than $200M from $5.68B previous guidance.2025 Guidance: Net revenue target increased to $9B-$10B vs. $7.86B previous estimate, and at least 10% revenue compound annual growth rate through 2025 and beyond...

- Robust pipeline of 20+ development programs across 7 rare disease franchises with future plans to continue growing pipeline with >5 novel INDs by 2025 - - Increasing depth and breadth of growth opportunities expected to generate 2025 global revenues of $9-10 billion &...

On September 30, BioCryst reported the results of BCX9930's Proof of Concept as an oral treatment for PNH as Monotherapy. The results have been very promising confirming the good expectations that existed. We can say without any doubt that BCX9930 has a good chance of becoming the...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...